Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Outcomes of patients with Hodgkin lymphoma undergoing alloHSCT after pembrolizumab therapy

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, comments on the results of a study assessing the safety of allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with classical Hodgkin lymphoma (HL) previously treated with pembrolizumab. Overall, whilst the study did not find a significant difference in efficacy when compared with historical controls, it reported a higher rate of acute graft-versus-host disease (GvHD) in patients treated with pembrolizumab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Karyopharma, DSB; Honoraria from Karyopharma, Merck; Research funding from Merck